Clinical trial
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
NCT00170781 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00170781 |
|---|---|
| Title | Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout |
| Official title | A 1-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel Trial Comparing Lumiracoxib (400 mg Once Daily) in Patients With Acute Flares of Gout, Using Indomethacin (50 mg Three Times a Day) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acute Gouty Arthritis |
| Intervention type | Drug |
| Interventions | Lumiracoxib |
| Enrollment | 234 |
| Start date | Jun 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 30, 2006 |
| Countries | Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: